Attached files
file | filename |
---|---|
EX-99.2 - EXHIBIT 99.2 - Aevi Genomic Medicine, Inc. | tv488321_ex99-2.htm |
EX-99.1 - EXHIBIT 99.1 - Aevi Genomic Medicine, Inc. | tv488321_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
March 13, 2018
Date of Report (Date of earliest event reported)
AEVI GENOMIC MEDICINE, INC.
(Exact name of registrant as specified in its charter)
Delaware | 1-35112 | 98-0217544 |
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
435 Devon Park Drive, Suite 715
Wayne, Pennsylvania 19087
(Address of principal executive offices, zip code)
(610) 254-4201
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. | Results of Operations and Financial Condition. |
On March 13, 2018, Aevi Genomic Medicine, Inc., a Delaware corporation (the “Company”), issued a press release regarding its financial results for the three and twelve months ended December 31, 2017. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
On March 13, 2018, the Company also made available on its website at www.aevigenomics.com presentation materials that it intends to use in connection with its conference call that is scheduled to begin at 8:30 a.m. E.T., Tuesday, March 13, 2018 regarding its quarter and year ended December 31, 2017 financial results (the “Presentation Deck”). A copy of the Presentation Deck is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information contained in this Item 2.02 as well as in Item 7.01 and Exhibit 99.1 and Exhibit 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933.
Item 7.01. | Regulation FD Disclosure. |
See Item 2.02 above regarding the Presentation Deck.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits. The following exhibits are furnished herewith:
Exhibit No. | Description |
99.1 | Aevi Genomic Medicine, Inc. Press Release dated March 13, 2018. |
99.2 | Presentation Deck dated March 13, 2018. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AEVI GENOMIC MEDICINE, INC. | |||
By: | /s/ Brian D. Piper | ||
Name: Brian D. Piper | |||
Title: Chief Financial Officer |
Date: March 13, 2018
EXHIBIT INDEX
Exhibit No. | Description |
99.1 | Aevi Genomic Medicine, Inc. Press Release dated March 13, 2018. |
99.2 | Presentation Deck dated March 13, 2018. |